{"protocolSection":{"identificationModule":{"nctId":"NCT04002700","orgStudyIdInfo":{"id":"CR108624"},"secondaryIdInfos":[{"id":"PCSESP001292","type":"OTHER","domain":"Janssen Research & Development, LLC"}],"organization":{"fullName":"Janssen Research & Development, LLC","class":"INDUSTRY"},"briefTitle":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","officialTitle":"Stroke Risk Among Users of Typical vs. Atypical Antipsychotics Stratified by Broad Age Group, a Post-authorization Safety Study"},"statusModule":{"statusVerifiedDate":"2019-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-05-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-05-31","type":"ACTUAL"},"completionDateStruct":{"date":"2019-05-31","type":"ACTUAL"},"studyFirstSubmitDate":"2019-06-28","studyFirstSubmitQcDate":"2019-06-28","studyFirstPostDateStruct":{"date":"2019-07-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-08-08","lastUpdatePostDateStruct":{"date":"2019-08-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and did not have dementia to participants aged 65 years and older regardless of dementia status."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":1234412,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Target Cohort 1","description":"Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years without a recent dementia diagnosis.","interventionNames":["Drug: Typical Antipsychotics"]},{"label":"Target Cohort 2","description":"Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years without a recent dementia diagnosis.","interventionNames":["Drug: Haloperidol"]},{"label":"Target Cohort 3","description":"Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged greater than or equal to (\\>=) 65 years.","interventionNames":["Drug: Typical Antipsychotics"]},{"label":"Target Cohort 4","description":"Participants will be analyzed for stroke-risk who are new users of haloperidol aged \\>= 65 year.","interventionNames":["Drug: Haloperidol"]},{"label":"Target Cohort 5","description":"Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years.","interventionNames":["Drug: Typical Antipsychotics"]},{"label":"Target Cohort 6","description":"Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years.","interventionNames":["Drug: Haloperidol"]},{"label":"Comparator Cohort 7","description":"Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years without a recent dementia diagnosis.","interventionNames":["Drug: Atypical Antipsychotics"]},{"label":"Comparator Cohort 8","description":"Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged \\>= 65 years.","interventionNames":["Drug: Atypical Antipsychotics"]},{"label":"Comparator Cohort 9","description":"Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years.","interventionNames":["Drug: Atypical Antipsychotics"]}],"interventions":[{"type":"DRUG","name":"Haloperidol","description":"Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.","armGroupLabels":["Target Cohort 2","Target Cohort 4","Target Cohort 6"]},{"type":"DRUG","name":"Typical Antipsychotics","description":"Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.","armGroupLabels":["Target Cohort 1","Target Cohort 3","Target Cohort 5"]},{"type":"DRUG","name":"Atypical Antipsychotics","description":"Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.","armGroupLabels":["Comparator Cohort 7","Comparator Cohort 8","Comparator Cohort 9"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Stroke as a Principal Inpatient Diagnosis","description":"Number of participants with stroke in each target cohort versus comparator cohort (aged 65 years and older) per person years at risk will be reported. It is defined defined by the presence of the relevant ICD codes (ICD-9 or ICD-10 according to date) in the inpatient setting as the primary diagnoses.","timeFrame":"Up to 16 years (from 01-January-2002 through 31-December-2017)"}],"secondaryOutcomes":[{"measure":"Number of Participants at Stroke Risk when Compared Among New Users of Typical Antipsychotics/Haloperidol versus Atypical Antipsychotics","description":"The number of participants with the risk of stroke among participants exposed to typical antipsychotics versus atypical antipsychotics will be reported.","timeFrame":"Up to 16 years (from 01-January-2002 through 31-December-2017)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor entry event of an initial drug exposure:\n\n* First exposure to the particular drug(s) in the past 183 days (index date)\n* Had at least 183 days of continuous observation time prior to index\n* Exactly 0 condition occurrences of 'Cancer' any time in the 183 days before or on the index date\n* Exactly 0 condition occurrences of 'Stroke' any time in the 183 days before or on the index date\n* Exactly 0 exposures to any other typical or atypical antipsychotics any time in the 183 days before or on the index date","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"The study population is the participants in (any of) the target or comparator cohorts. Each target and comparator cohort will be drawn from the appropriate database: IBM MarketScan Commercial Database (CCAE) if the participants are aged 18-64 years and IBM MarketScan Medicare Supplemental Database (MDCR) if participants are aged greater than or equal to (\\>=) 65 years.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Research & Development, LLC Clinical Trial","affiliation":"Janssen Research & Development, LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Janssen Investigative Site","city":"Titusville","state":"New Jersey","zip":"08560","country":"United States","geoPoint":{"lat":40.30955,"lon":-74.88044}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000006220","term":"Haloperidol"},{"id":"C000033563","term":"Haloperidol decanoate"},{"id":"D000014150","term":"Antipsychotic Agents"}],"ancestors":[{"id":"D000000932","term":"Antiemetics"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000005765","term":"Gastrointestinal Agents"},{"id":"D000014149","term":"Tranquilizing Agents"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000011619","term":"Psychotropic Drugs"},{"id":"D000018492","term":"Dopamine Antagonists"},{"id":"D000015259","term":"Dopamine Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018726","term":"Anti-Dyskinesia Agents"}],"browseLeaves":[{"id":"M1675","name":"Olanzapine","relevance":"LOW"},{"id":"M20689","name":"Risperidone","relevance":"LOW"},{"id":"M9002","name":"Haloperidol","asFound":"Whey","relevance":"HIGH"},{"id":"M215418","name":"Haloperidol decanoate","asFound":"Whey","relevance":"HIGH"},{"id":"M16594","name":"Antipsychotic Agents","asFound":"NAC","relevance":"HIGH"},{"id":"M5944","name":"Clozapine","relevance":"LOW"},{"id":"M5677","name":"Chlorpromazine","relevance":"LOW"},{"id":"M292983","name":"Brexpiprazole","relevance":"LOW"},{"id":"M292979","name":"Cariprazine","relevance":"LOW"},{"id":"M13144","name":"Perphenazine","relevance":"LOW"},{"id":"M254651","name":"Ziprasidone","relevance":"LOW"},{"id":"M259710","name":"Iloperidone","relevance":"LOW"},{"id":"M10840","name":"Loxapine","relevance":"LOW"},{"id":"M16710","name":"Trifluoperazine","relevance":"LOW"},{"id":"M347692","name":"Asenapine","relevance":"LOW"},{"id":"M8294","name":"Fluphenazine","relevance":"LOW"},{"id":"M16331","name":"Thioridazine","relevance":"LOW"},{"id":"M16337","name":"Thiothixene","relevance":"LOW"},{"id":"M11627","name":"Molindone","relevance":"LOW"},{"id":"M3941","name":"Antiemetics","relevance":"LOW"},{"id":"M8571","name":"Gastrointestinal Agents","relevance":"LOW"},{"id":"M14164","name":"Psychotropic Drugs","relevance":"LOW"},{"id":"M7163","name":"Dopamine","relevance":"LOW"},{"id":"M20286","name":"Dopamine Antagonists","relevance":"LOW"},{"id":"M17652","name":"Dopamine Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnEm","name":"Antiemetics"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"PsychDr","name":"Psychotropic Drugs"},{"abbrev":"Gast","name":"Gastrointestinal Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnDyAg","name":"Anti-Dyskinesia Agents"},{"abbrev":"CaAg","name":"Cardiotonic Agents"}]}},"hasResults":false}